MAPS PBC is entering into a collaboration that aims to bring its novel therapy for PTSD closer to regulatory evaluation.
The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) has confirmed it has now fully enroled its Phase III trial of MDMA-assisted therapy for PTSD.
Delic Holdings Corp subsidiary, Delic Labs, has received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on psychedelic and...
The trial MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has advanced to the next implementation phase.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.
Historically dubbed the “love drug” for its ability to induce sensual feelings and pro-social behaviour, MDMA is now being researched for a number of social and...
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
Mydecine has signed a Letter of Intent (LOI) with The Newly Institute to provide psychedelic-assisted psychotherapy to patients for Health Canada’s Special Access Program.
A new MoU will explore a partnership to utilise MDMA-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD) in Europe.
Psychedelics manufacturer Psygen has received the dealer’s license for LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline.
